Thirty-five years of noninvasive bladder carcinoma: A plea for the use of papillary intraurothelial neoplasia as new terminology

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 6, 2008, Pages 309-315

  Van Der Kwast, Theodoras H ^a,e   Zlotta, Alexandre R ^b   Fleshner, Neil ^b   Jewett, Michael ^b   Lopez Beltran, Antonio ^c   Montironi, Roldolfo ^d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bladder cancer; Nomenclature; Papillary urothelial carcinoma; Papillary urothelial neoplasm of low malignant potential; WHO 2004 classification

Indexed keywords

BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CARCINOMA IN SITU; DYSPLASIA; EVIDENCE BASED PRACTICE; GENE MUTATION; HUMAN; MOLECULAR GENETICS; NOMENCLATURE; PAPILLARY CARCINOMA; PAPILLARY INTRAUROTHELIAL NEOPLASIA; PRIORITY JOURNAL; REVIEW; WORLD HEALTH ORGANIZATION;

ANIMALS; CARCINOMA, PAPILLARY; HUMANS; MOLECULAR BIOLOGY; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; TERMINOLOGY AS TOPIC; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 57649178026     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Mostofi FK, Sobin LH, Torloni H: Histologic typing of urinary bladder tumors. In International Histological Classification of Tumors, No. 10. Geneva, World Health Organization, 1973
2. Sobin LH: The WHO histological classification of urinary bladder tumors. Urol Res 1978;6:193-195
3. Harnden P: A critical appraisal of the classification of urothelial tumors: Time for a review of the evidence and a radical change? Br J Urol Int 2006;99:723-730
4. Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder: Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-1448
5. Holmäng S, Hedelin H, Anderström C, Holmberg E, Busch C, Johansson SL: Recurrence and progression in low grade papillary urothelial tumors. J Urol 1999;162:702-707
6. Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, Grignon D, Hofstädter F, Lopez-Beltran A, Epstein JI: Noninvasive urothelial tumors. In World Health Organization Classification of Tumors, Pathology and Genetics: Tumors of the Urinary System and Male Genital Organs. Edited by JN Eble, G Sauter, JI Epstein, I Sesterhenn. Lyon, IARC Press, 2004, p 110
7. Murphy WM, Takezawa K, Maruniak NA: Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: Practical choices for patient care. J Urol 2002;168:968-972
8. Yorukoglu K, Tuna B, Dikicioglu E, Duzcan E, Isisag A, Sen S, Mungan U, Kirkali Z: Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Arch 2003;443:734-740
9. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O, Øgreid P: Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169:1291-1294
10. Jones TD, Cheng L: Papillary urothelial neoplasm of low malignant potential: Evolving terminology and concepts. J Urol 2006;175:1995-2003
11. Mack D, Frick J: Quality of life in patients undergoing bacille Calmette-Guérin therapy for superficial bladder cancer. Br J Urol 1996;78:369-371
12. Ossepowitch O, Herr HW, Donat SM: Use of urinary biomarkers for bladder cancer surveillance: Patient perspectives. J Urol 2007;177:1277-1282
13. Herr HW, Donat SM, Reuter VE: Management of low grade papillary bladder tumors. J Urol 2007;178:1201-1205
14. Lotan Y, Roehrborn CG: Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J Urol 2002;167:75-79
15. Vriesema JL, Poucki MH, Kiemeney LA, Witjes JA: Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: A utility analysis. Urology 2000;56:793-797
16. Van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005;47:736-748
17. Kiemeney LA, Coebergh JW, Koper NP, van der Heijden LH, Pauwels RP, Schapers RF, Verbeek AL: Bladder cancer incidence and survival in the south-eastern part of The Netherlands, 1975-1989. Eur J Cancer 1994;30A:1134-1137
18. Welin S, Youker J, Spratt JS Jr: The rates and patterns of growth of 375 tumors of the large intestine and rectum observed serially by double contrast enema study (Malmoe Technique). Am J Roentgenol Radium Ther Nucl Med 1963; 90:673-687
19. Kakkebaek NE, Berthelsen JG, Giwercman A, Müller J: Carcinoma-in-situ of the testis: Possible origin from gonocytes and precursor of all types of germ cell tumors except spermatocytoma. Int J Androl 1987;10:19-28
20. Soloway MS, Bruck DS, Kim SS: Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 2003;170:438-441
21. Pruthi RS, Baldwin N, Bhalani V, Wallen EM: Conservative management of low risk superficial bladder tumors. J Urol 2008;179:87-90
22. Gupta SK, Parr NJ: Outcome of very large superficial bladder tumors: A 10-year experience. Scand J Urol Nephrol 2008;42:243-248
23. Soloway MS, Masters S: Urothelial susceptibility to tumor cell implantation: Influence of cauterization. Cancer 1980;46: 1158-1163
24. Merz BJ, Dodge GG, Abella RM, Kisken WA: Implant metastasis of gallbladder carcinoma in situ in a cholecystectomy scar: A case report. Surgery 1993;114:120-124
25. Obermann EC, Junker K, Stoehr R, Dietmaier W, Zaak D, Schubert J, Hofstaedter F, Knuechel R, Hartmann A: Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003;199:50-57
26. Van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH: Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198:245-251
27. Chow NH, Cairns P, Eisenberger CF, Schoenberg MP, Taylor DC, Epstein JI, Sidransky D: Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000;89:514-518
28. Logie A, Dunois-Larde C, Rosty C, Levrel O, Blanche M, Ribeiro A, Gasc JM, Jorcano J, Werner S, Sastre-Garau X, Thiery JP, Radvanyi F: Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005;14:1153-1160
29. Cheng L, MacLennan GT, Zhang S, Wang M, Pan CX, Koch MO: Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer 2004;101:183-188
30. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB: Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low grade papillary urothelial tumors: World Health Organization/International Society of Urologic Pathology. Mod Pathol 2001; 14:267-272
31. Montironi R, Lopez-Beltran A, Mazzucchelli R, Bostwick DG: Classification and grading of the noninvasive urothelial neoplasms: Recent advances and controversies. J Clin Pathol 2003;56:91-95
32. Cina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI: Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med 2001;125:646-651
33. Zieger K, Dyrskjot L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Orntoft TF: Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res 2005;11:7709-7719
34. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG: FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-8112
35. Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG: Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. Cancer 2000;88: 1663-1670
36. Tomlinson DC, Baldo O, Harnden P, Knowles MA: FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213: 91-98
37. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K, von der Maase H, Orntoft TF: High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005;65:34-45
38. Sun W, Herrera GA: E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 2002;33:996-1000
39. Dhawan D, Hamdy FC, Rehman I, Patterson J, Cross SS, Feeley KM, Stephenson Y, Meuth M, Catto JW: Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma. J Pathol 2006;209:336-343
40. Dyrskjot L: Identifying distinct classes of bladder carcinoma using microarrays. Nature Genet 2003;33:90-96
41. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K, Devries S, Koppie T, Pejavar S, Carroll P, Waldman FM: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11:4044-4055
42. Novelli MR, Williamson JA, Tomlinson IP, Elia G, Hodgson SV, Talbot IC, Bodmer WF, Wright NA: Polyclonal origin of colonic adenomas in an XO/XY patient with FAP. Science 1996;272:1187-1190